Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ATTENTION CORT Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky Ready to Announce with Confidence?

newsfilecorp.com
CORT The article reports a securities fraud investigation into Corcept Therapeutics due to a CRL from the FDA denying drug approval, causing a significant stock price drop and a new 52-week low. BSX RGNX Mentioned as a company under investigation by Levi & Korsinsky for potentially misleading shareholders, but no specific details about the investigation's nature or impact are provided. PYPL Mentioned as a company under investigation by Levi & Korsinsky, but no specific details about the investigation's nature or impact on the company's stock are provided.

New York, New York--(Newsfile Corp. - February 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ: CORT) concerning potential violations of the federal securities laws.

What Happened?

On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept's new drug application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.

According to the Company's release, the FDA acknowledged the results of the previous GRACE and GRADIENT drug trials, but "concluded it could not arrive at a favorable benefit-risk assessment for relacordilant without Corcept providing additional evidence of effectiveness".

Why it Matters:

Today, in direct response to this news, Corcept's stock price fell by $31.42 (44.76%) per share to open at $38.78 per share on December 31, 2025.

This drop marks a new 52-week low for Corcept's stock, dropping to levels not seen since September 2024.

If you suffered a loss on your Corcept Therapeutics Incorporated securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212)363-7500

Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283169

Source: Levi & Korsinsky, LLP

Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.

Fraud Investigation Opened: Levi & Korsinsky Investigates Boston Scientific Corporation (BSX) on Behalf of Shareholders

2026-02-09 12:27 AM EST

Ongoing Investigation: REGENXBIO Inc. (RGNX) May Have Misled Shareholders - Levi & Korsinsky Investigates

2026-02-09 12:21 AM EST

Ongoing Securities Investigation into PayPal Holdings, Inc. (PYPL) - Contact Levi & Korsinsky

2026-02-09 12:16 AM EST

Sep 29, 2025

AI isn’t just a future trend. It’s already reshaping how press releases are read, shared, and discovered today. The audience for your news is no longer only human. Journalists, analysts, and investors still matter, but now AI systems are scanning, indexing, and summarizing your announcements at scale. Here are a few numbers that show the size of this shift: 78% of companies now use AI in at least one function ( McKinsey, 2025 ) 92% of Fortune 500 companies are using OpenAI's technology (...

Economy, Business and Finance

Legal Service

Litigation and Regulation

Banking / Financial Services